ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration
11. Dezember 2024 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 11, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA...
Anavex Life Sciences Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
12. Januar 2024 10:10 ET
|
Block & Leviton LLP
BOSTON, Jan. 12, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Anavex Life Sciences Corp. (NASDAQ: AVXL) for potential securities law violations. Investors who have lost money in...
ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration
05. Januar 2024 07:00 ET
|
ProQR Therapeutics N.V.
Partnership focused on utilizing Axiomer™ to develop editing oligonucleotides targeting an underlying genetic variant that causes Rett syndromeCollaboration expands ProQR’s commitment to advance the...
Anavex Life Sciences Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
03. Januar 2024 12:14 ET
|
Block & Leviton LLP
BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Anavex Life Sciences Corp. (NASDAQ: AVXL) for potential securities law violations. Investors who have lost money in...
Vyant Bio Presents Key Takeaways from Platform and Poster Presentations at Neuroscience 2022 Hosted by the Society for Neuroscience
16. November 2022 17:05 ET
|
Vyant Bio, Inc.
“Targeting specific functional rescue in a Rett patient cortical organoid disease model” CHERRY HILL, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq:...
Vyant Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
16. November 2022 16:43 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...
Vyant Bio Presents Key Takeaways from Platform and Poster Presentations at the 2022 CDKL5 Forum Hosted by the Loulou Foundation
10. November 2022 17:13 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...
Vyant Bio Announces Participation at the 2022 CDKL5 Forum Hosted by the Loulou Foundation on November 7-8, 2022
27. Oktober 2022 17:10 ET
|
Vyant Bio, Inc.
Platform and Poster Presentations on Vyant Bio’s Human First Drug Discovery Platform and Progress on CDKL5 Deficiency Disorder (CDD) CHERRY HILL, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Vyant...
Vyant Bio Reports First Quarter 2022 Results and Provides Strategic and Business Highlights
16. Mai 2022 08:30 ET
|
Vyant Bio, Inc.
Conference Call and Webcast Today at 4:30 pm ET Scientific and Business Highlights ●Progress in the discovery of small molecule therapeutics to treat neurodevelopmental and...
AVXL NOTICE: ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Inquire About Securities Class Action Investigation – AVXL
20. Februar 2022 13:30 ET
|
The Rosen Law Firm PA
NEW YORK, Feb. 20, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Anavex Life...